1. Home
  2. PBYI vs RMNI Comparison

PBYI vs RMNI Comparison

Compare PBYI & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • RMNI
  • Stock Information
  • Founded
  • PBYI 2010
  • RMNI 2005
  • Country
  • PBYI United States
  • RMNI United States
  • Employees
  • PBYI N/A
  • RMNI N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • RMNI Business Services
  • Sector
  • PBYI Health Care
  • RMNI Consumer Discretionary
  • Exchange
  • PBYI Nasdaq
  • RMNI Nasdaq
  • Market Cap
  • PBYI 153.2M
  • RMNI 245.5M
  • IPO Year
  • PBYI N/A
  • RMNI N/A
  • Fundamental
  • Price
  • PBYI $3.09
  • RMNI $2.68
  • Analyst Decision
  • PBYI Strong Buy
  • RMNI Buy
  • Analyst Count
  • PBYI 1
  • RMNI 2
  • Target Price
  • PBYI $7.00
  • RMNI $6.00
  • AVG Volume (30 Days)
  • PBYI 754.5K
  • RMNI 538.6K
  • Earning Date
  • PBYI 02-27-2025
  • RMNI 02-26-2025
  • Dividend Yield
  • PBYI N/A
  • RMNI N/A
  • EPS Growth
  • PBYI 492.79
  • RMNI N/A
  • EPS
  • PBYI 0.47
  • RMNI N/A
  • Revenue
  • PBYI $243,569,000.00
  • RMNI $426,650,000.00
  • Revenue This Year
  • PBYI N/A
  • RMNI N/A
  • Revenue Next Year
  • PBYI N/A
  • RMNI N/A
  • P/E Ratio
  • PBYI $6.63
  • RMNI N/A
  • Revenue Growth
  • PBYI 6.30
  • RMNI N/A
  • 52 Week Low
  • PBYI $2.23
  • RMNI $1.53
  • 52 Week High
  • PBYI $7.73
  • RMNI $3.43
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.17
  • RMNI 56.80
  • Support Level
  • PBYI $2.92
  • RMNI $2.50
  • Resistance Level
  • PBYI $4.06
  • RMNI $2.86
  • Average True Range (ATR)
  • PBYI 0.29
  • RMNI 0.19
  • MACD
  • PBYI 0.01
  • RMNI -0.02
  • Stochastic Oscillator
  • PBYI 27.07
  • RMNI 45.24

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About RMNI Rimini Street Inc. (DE)

Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.

Share on Social Networks: